Reducing the Burden and Improving QoL in Non-Cystic Fibrosis Bronchiectasis: Insights on Challenging Cases
Provided by RMEI Medical Education, LLC
Pulmonology, infectious diseases, primary care, and radiology clinicians managing patients with NCFBE
Upon completion of this activity, participants should be better able to:
- Utilize clinical practice guidelines for non-cystic fibrosis bronchiectasis (NCFBE) diagnosis
- Integrate the unique roles and responsibilities of the interprofessional care team when diagnosing and treating patients with NCFBE
- Examine emerging treatments targeting the underlying immune mediated pathophysiologic processes of NCFBE
Mark L. Metersky, MD, FCCP (Chair)
Associate Chief of Service, Department of Medicine
Chief, Division of Pulmonary, Critical Care and Sleep Medicine
Director, Center for Bronchiectasis Care
Margaret M. Johnson, MD
Mayo Clinic College of Medicine and Science
Consultant, Pulmonary Medicine
Molly Mailes, MSN, RN, MEDSURG-BC
Nurse Program Coordinator, Adult Cystic Fibrosis
Disclosure of Financial Relationships
RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.
Margaret M. Johnson, MD, has no relevant financial relationship(s) with ineligible companies to disclose.
Molly Mailes, MSN, RN, MEDSURG-BC, has no relevant financial relationship(s) with ineligible companies to disclose.
Mark L. Metersky, MD, FCCP, has relevant financial relationships with Boehringer Ingelheim, Insmed, Tactile Medical, Zambon (Consultant); AN2, Renovion (Other: Data Safety Monitoring Board); Insmed (Researcher).
All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.
Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.
Joint Accreditation Statement
In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).
Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Method of Participation and Request for Credit
In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at firstname.lastname@example.org.
- Read the learning objectives and faculty disclosures
- Participate in the activity
- Complete the activity evaluation and attest to credit
There is no fee to participate.
Statement of Commercial Support
This activity is supported by an educational grant from Insmed.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.